Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Drug Resistance, Neoplasm
Drug Therapy, Combination
Female
Granulocyte-Macrophage Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Humans
Immunomodulation
Immunotherapy
Interleukin-2
Lymphoma, Non-Hodgkin
Male
Middle Aged
Neoplasm Staging
Rituximab
Salvage Therapy
Survival Rate
Transplantation, Autologous
Treatment Outcome
Young Adult

authors with profiles

Justin P. Kline
Thomas F. Gajewski
David L. Grinblatt
Koen Van Besien